279 related articles for article (PubMed ID: 37435085)
21. Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response.
Gangaev A; Rozeman EA; Rohaan MW; Isaeva OI; Philips D; Patiwael S; van den Berg JH; Ribas A; Schadendorf D; Schilling B; Schumacher TN; Blank CU; Haanen JBAG; Kvistborg P
Proc Natl Acad Sci U S A; 2021 Oct; 118(43):. PubMed ID: 34670835
[TBL] [Abstract][Full Text] [Related]
22. Innate immune checkpoint inhibitor resistance is associated with melanoma sub-types exhibiting invasive and de-differentiated gene expression signatures.
Hossain SM; Gimenez G; Stockwell PA; Tsai P; Print CG; Rys J; Cybulska-Stopa B; Ratajska M; Harazin-Lechowska A; Almomani S; Jackson C; Chatterjee A; Eccles MR
Front Immunol; 2022; 13():955063. PubMed ID: 36248850
[TBL] [Abstract][Full Text] [Related]
23. Immune Checkpoint Inhibitor-Induced Thyroiditis Is Associated with Increased Intrathyroidal T Lymphocyte Subpopulations.
Kotwal A; Gustafson MP; Bornschlegl S; Kottschade L; Delivanis DA; Dietz AB; Gandhi M; Ryder M
Thyroid; 2020 Oct; 30(10):1440-1450. PubMed ID: 32323619
[No Abstract] [Full Text] [Related]
24. Skin immunization for effective treatment of multifocal melanoma refractory to PD1 blockade and Braf inhibitors.
Hao X; Falo Iii LD; Chen G; Zhang J; Carey CD; Storkus WJ; Falo LD; You Z
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33408093
[TBL] [Abstract][Full Text] [Related]
25. PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy.
Simon S; Voillet V; Vignard V; Wu Z; Dabrowski C; Jouand N; Beauvais T; Khammari A; Braudeau C; Josien R; Adotevi O; Laheurte C; Aubin F; Nardin C; Rulli S; Gottardo R; Ramchurren N; Cheever M; Fling SP; Church CD; Nghiem P; Dreno B; Riddell SR; Labarriere N
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33188038
[TBL] [Abstract][Full Text] [Related]
26. [Detection of peripheral follicular helper T cells in rheumatoid arthritis].
An LM; Li J; Ji LL; Li GT; Zhang ZL
Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Dec; 48(6):951-957. PubMed ID: 27987496
[TBL] [Abstract][Full Text] [Related]
27. Host response to immune checkpoint inhibitors contributes to tumor aggressiveness.
Khononov I; Jacob E; Fremder E; Dahan N; Harel M; Raviv Z; Krastev B; Shaked Y
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33707313
[TBL] [Abstract][Full Text] [Related]
28. Boiling histotripsy and in-situ CD40 stimulation improve the checkpoint blockade therapy of poorly immunogenic tumors.
Singh MP; Sethuraman SN; Miller C; Malayer J; Ranjan A
Theranostics; 2021; 11(2):540-554. PubMed ID: 33391491
[No Abstract] [Full Text] [Related]
29. Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor-Induced Myocarditis.
Zhu H; Galdos FX; Lee D; Waliany S; Huang YV; Ryan J; Dang K; Neal JW; Wakelee HA; Reddy SA; Srinivas S; Lin LL; Witteles RM; Maecker HT; Davis MM; Nguyen PK; Wu SM
Circulation; 2022 Jul; 146(4):316-335. PubMed ID: 35762356
[TBL] [Abstract][Full Text] [Related]
30.
Cheng Y; Lemke-Miltner CD; Wongpattaraworakul W; Wang Z; Chan CHF; Salem AK; Weiner GJ; Simons AL
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33060147
[TBL] [Abstract][Full Text] [Related]
31. The immune microenvironment of HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma: a multiparametric quantitative and spatial analysis unveils a rationale to target treatment-naïve tumors with immune checkpoint inhibitors.
Tosi A; Parisatto B; Menegaldo A; Spinato G; Guido M; Del Mistro A; Bussani R; Zanconati F; Tofanelli M; Tirelli G; Boscolo-Rizzo P; Rosato A
J Exp Clin Cancer Res; 2022 Sep; 41(1):279. PubMed ID: 36123711
[TBL] [Abstract][Full Text] [Related]
32. Adenovirus Encoding Tumor Necrosis Factor Alpha and Interleukin 2 Induces a Tertiary Lymphoid Structure Signature in Immune Checkpoint Inhibitor Refractory Head and Neck Cancer.
Clubb JHA; Kudling TV; Heiniö C; Basnet S; Pakola S; Cervera Carrascón V; Santos JM; Quixabeira DCA; Havunen R; Sorsa S; Zheng V; Salo T; Bäck L; Aro K; Tulokas S; Loimu V; Hemminki A
Front Immunol; 2022; 13():794251. PubMed ID: 35355980
[TBL] [Abstract][Full Text] [Related]
33. Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy.
Wang Y; Liu S; Yang Z; Algazi AP; Lomeli SH; Wang Y; Othus M; Hong A; Wang X; Randolph CE; Jones AM; Bosenberg MW; Byrum SD; Tackett AJ; Lopez H; Yates C; Solit DB; Ribas A; Piva M; Moriceau G; Lo RS
Cancer Cell; 2021 Oct; 39(10):1375-1387.e6. PubMed ID: 34416167
[TBL] [Abstract][Full Text] [Related]
34.
Zhou S; Zhang S; Zheng K; Li Z; Hu E; Mu Y; Mai J; Zhao A; Zhao Z; Li F
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38302417
[TBL] [Abstract][Full Text] [Related]
35. CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma.
Bozhanova G; Hassan J; Appleton L; Jennings V; Foo S; McLaughlin M; Chan Wah Hak CM; Patin EC; Crespo-Rodriguez E; Baker G; Armstrong E; Chiu M; Pandha H; Samson A; Roulstone V; Kyula J; Vile R; Errington-Mais F; Pedersen M; Harrington K; Ono M; Melcher A
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338089
[TBL] [Abstract][Full Text] [Related]
36. Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma.
Serratì S; Guida M; Di Fonte R; De Summa S; Strippoli S; Iacobazzi RM; Quarta A; De Risi I; Guida G; Paradiso A; Porcelli L; Azzariti A
Mol Cancer; 2022 Jan; 21(1):20. PubMed ID: 35042524
[TBL] [Abstract][Full Text] [Related]
37. Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4
Kovacsovics-Bankowski M; Sweere JM; Healy CP; Sigal N; Cheng LC; Chronister WD; Evans SA; Marsiglio J; Gibson B; Swami U; Erickson-Wayman A; McPherson JP; Derose YS; Eliason AL; Medina CO; Srinivasan R; Spitzer MH; Nguyen N; Hyngstrom J; Hu-Lieskovan S
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38233101
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of tumor response to immune checkpoint inhibitors by a 3D immunotumoroid model.
Pezeshki A; Cheville JC; Florio AB; Leibovich BC; Vasmatzis G
Front Immunol; 2024; 15():1356144. PubMed ID: 38605943
[TBL] [Abstract][Full Text] [Related]
39. A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer.
Bassez A; Vos H; Van Dyck L; Floris G; Arijs I; Desmedt C; Boeckx B; Vanden Bempt M; Nevelsteen I; Lambein K; Punie K; Neven P; Garg AD; Wildiers H; Qian J; Smeets A; Lambrechts D
Nat Med; 2021 May; 27(5):820-832. PubMed ID: 33958794
[TBL] [Abstract][Full Text] [Related]
40. 9-Gene Signature Correlated With CD8
Yan K; Lu Y; Yan Z; Wang Y
Front Immunol; 2021; 12():622563. PubMed ID: 34220795
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
